# Armata Pharmaceuticals, Inc.: financial statements, quarterly

ARMP · NYSE · CIK 921114 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/armp.md) · [Financials](/companies/armp/financials.md) · [Filings](/companies/armp/filings.md) · [Insiders](/companies/armp/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/armp/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Research and development | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating income | $m | [(10.3)](/filings/0001558370-24-015530.md) | [(9.6) d](/filings/0001558370-25-003406.md) | [(10.2)](/filings/0001558370-25-007765.md) | [(11.9)](/filings/0001558370-25-011235.md) | [(9.8)](/filings/0001104659-25-110383.md) | [(10.5) d](/filings/0001104659-26-034532.md) | [(8.2)](/filings/0001104659-26-060333.md) | [(6.8)](/filings/0001104659-26-094907.md) | [(7.8)](/filings/0001104659-25-110383.md) | [(13.8) d](/filings/0001104659-26-034532.md) | [(8.8)](/filings/0001104659-26-060333.md) | [(10.3)](/filings/0001104659-26-094907.md) |
| Interest expense | $m | [1.2](/filings/0001558370-23-019036.md) | not reported | [1.8](/filings/0001558370-24-007068.md) | [2.7](/filings/0001558370-24-012061.md) | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [0.0](/filings/0001558370-24-015530.md) | not reported | [0.0](/filings/0001558370-25-011235.md) | [0.0](/filings/0001558370-24-012061.md) | [0.0](/filings/0001104659-25-110383.md) | not reported | [0.0](/filings/0001104659-26-060333.md) | [0.0 d](/filings/0001104659-26-094907.md) | [0.0](/filings/0001104659-25-110383.md) | not reported | [0.0](/filings/0001104659-26-060333.md) | [0.0 d](/filings/0001104659-26-094907.md) |
| Net income | $m | [(31.2)](/filings/0001558370-24-015530.md) | [(19.8) d](/filings/0001558370-25-003406.md) | [(25.0)](/filings/0001558370-25-007765.md) | [9.0](/filings/0001558370-25-011235.md) | [(5.5)](/filings/0001104659-25-110383.md) | [2.6 d](/filings/0001104659-26-034532.md) | [(6.5)](/filings/0001104659-26-060333.md) | [(16.3)](/filings/0001104659-26-094907.md) | [(26.7)](/filings/0001104659-25-110383.md) | [(124) d](/filings/0001104659-26-034532.md) | [(115)](/filings/0001104659-26-060333.md) | [74.1](/filings/0001104659-26-094907.md) |
| Diluted EPS | $ per share | [(0.86)](/filings/0001558370-24-015530.md) | not reported | [(0.69)](/filings/0001558370-25-007765.md) | [(0.25)](/filings/0001558370-25-011235.md) | [(0.15)](/filings/0001104659-25-110383.md) | not reported | [(0.20)](/filings/0001104659-26-060333.md) | [(0.45)](/filings/0001104659-26-094907.md) | [(0.74)](/filings/0001104659-25-110383.md) | not reported | [(3.16)](/filings/0001104659-26-060333.md) | [(0.27)](/filings/0001104659-26-094907.md) |
| Basic EPS | $ per share | [(0.86)](/filings/0001558370-24-015530.md) | not reported | [(0.69)](/filings/0001558370-25-007765.md) | [0.25](/filings/0001558370-25-011235.md) | [(0.15)](/filings/0001104659-25-110383.md) | not reported | [(0.18)](/filings/0001104659-26-060333.md) | [(0.45)](/filings/0001104659-26-094907.md) | [(0.74)](/filings/0001104659-25-110383.md) | not reported | [(3.16)](/filings/0001104659-26-060333.md) | [2.02](/filings/0001104659-26-094907.md) |

- Revenue: not reported
- Research and development: not reported
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [24.0](/filings/0001558370-24-015530.md) | [13.5](/filings/0001558370-25-003406.md) | [37.9](/filings/0001558370-25-007765.md) | [26.4](/filings/0001558370-25-011235.md) | [17.1](/filings/0001104659-25-110383.md) | [9.3](/filings/0001104659-26-034532.md) | [11.7](/filings/0001104659-26-060333.md) | [4.3](/filings/0001104659-26-094907.md) | [14.8](/filings/0001104659-25-110383.md) | [8.7](/filings/0001104659-26-094907.md) | [4.8](/filings/0001104659-26-060333.md) | [24.0](/filings/0001104659-26-094907.md) |
| Current assets | $m | [36.6](/filings/0001558370-23-019036.md) | [19.2](/filings/0001558370-25-003406.md) | [41.7](/filings/0001558370-24-007068.md) | [30.9](/filings/0001558370-24-012061.md) | [22.4](/filings/0001558370-24-015530.md) | [11.3](/filings/0001104659-26-034532.md) | [13.2](/filings/0001558370-25-007765.md) | [7.5](/filings/0001558370-25-011235.md) | [16.9](/filings/0001104659-25-110383.md) | [10.7](/filings/0001104659-26-094907.md) | [5.9](/filings/0001104659-26-060333.md) | [27.2](/filings/0001104659-26-094907.md) |
| Total assets | $m | [113](/filings/0001558370-23-019036.md) | [98.4](/filings/0001558370-25-003406.md) | [120](/filings/0001558370-24-007068.md) | [108](/filings/0001558370-24-012061.md) | [98.2](/filings/0001558370-24-015530.md) | [86.4](/filings/0001104659-26-034532.md) | [87.3](/filings/0001558370-25-007765.md) | [80.8](/filings/0001558370-25-011235.md) | [89.5](/filings/0001104659-25-110383.md) | [76.9](/filings/0001104659-26-094907.md) | [69.8](/filings/0001104659-26-060333.md) | [90.0](/filings/0001104659-26-094907.md) |
| Current liabilities | $m | [21.9](/filings/0001558370-23-019036.md) | [16.5](/filings/0001558370-25-003406.md) | [110](/filings/0001558370-24-007068.md) | [123](/filings/0001558370-24-012061.md) | [118](/filings/0001558370-24-015530.md) | [48.2](/filings/0001104659-26-034532.md) | [111](/filings/0001558370-25-007765.md) | [120](/filings/0001558370-25-011235.md) | [140](/filings/0001104659-25-110383.md) | [8.9](/filings/0001104659-26-094907.md) | [9.2](/filings/0001104659-26-060333.md) | [250](/filings/0001104659-26-094907.md) |
| Total liabilities | $m | [125](/filings/0001558370-23-019036.md) | [130](/filings/0001558370-25-003406.md) | [177](/filings/0001558370-24-007068.md) | [154](/filings/0001558370-24-012061.md) | [149](/filings/0001558370-24-015530.md) | [134](/filings/0001104659-26-034532.md) | [141](/filings/0001558370-25-007765.md) | [150](/filings/0001558370-25-011235.md) | [185](/filings/0001104659-25-110383.md) | [295](/filings/0001104659-26-094907.md) | [381](/filings/0001104659-26-060333.md) | [321](/filings/0001104659-26-094907.md) |
| Shareholders' equity | $m | [(12.4)](/filings/0001558370-24-015530.md) | [(32.1)](/filings/0001104659-26-034532.md) | [(56.5)](/filings/0001558370-25-011235.md) | [(46.1)](/filings/0001104659-25-110383.md) | [(51.0)](/filings/0001104659-25-110383.md) | [(48.0)](/filings/0001104659-26-094907.md) | [(53.8)](/filings/0001104659-26-094907.md) | [(69.5)](/filings/0001104659-26-094907.md) | [(95.6)](/filings/0001104659-25-110383.md) | [(219)](/filings/0001104659-26-094907.md) | [(312)](/filings/0001104659-26-094907.md) | [(231)](/filings/0001104659-26-094907.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [(9.7) d](/filings/0001558370-24-015530.md) | [(8.1) d](/filings/0001558370-25-003406.md) | [(10.6)](/filings/0001558370-25-007765.md) | [(10.2) d](/filings/0001558370-25-011235.md) | [(8.9) d](/filings/0001104659-25-110383.md) | [(7.9) d](/filings/0001104659-26-034532.md) | [(7.6)](/filings/0001104659-26-060333.md) | [(7.2) d](/filings/0001104659-26-094907.md) | [(4.3) d](/filings/0001104659-25-110383.md) | [(6.7) d](/filings/0001104659-26-034532.md) | [(5.8)](/filings/0001104659-26-060333.md) | [(8.7) d](/filings/0001104659-26-094907.md) |
| Capital expenditure | $m | [3.5 d](/filings/0001558370-24-015530.md) | [2.4 d](/filings/0001558370-25-003406.md) | [0.3](/filings/0001558370-25-007765.md) | [1.4 d](/filings/0001558370-25-011235.md) | [0.3 d](/filings/0001104659-25-110383.md) | [(0.1) d](/filings/0001104659-26-034532.md) | [0.1](/filings/0001104659-26-060333.md) | [0.1 d](/filings/0001104659-26-094907.md) | [0.2 d](/filings/0001104659-25-110383.md) | [0.1 d](/filings/0001104659-26-034532.md) | [0.1](/filings/0001104659-26-060333.md) | [0.0 d](/filings/0001104659-26-094907.md) |
| Dividends paid | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
- Dividends paid: not reported

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [36.0](/filings/0001558370-23-019036.md) | [36.0](/filings/0001558370-24-007068.md) | [56.5](/filings/0001558370-24-012061.md) | [36.1](/filings/0001558370-24-015530.md) | [36.1](/filings/0001558370-25-007765.md) | [58.2](/filings/0001558370-25-011235.md) | [36.2](/filings/0001104659-25-110383.md) | [59.5](/filings/0001104659-26-060333.md) | [36.2](/filings/0001104659-26-094907.md) | [36.2](/filings/0001104659-25-110383.md) | [36.5](/filings/0001104659-26-060333.md) | [62.0](/filings/0001104659-26-094907.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Shares outstanding: 37,181,979 at 2026-08-06, from the cover of the [10-Q filed 2026-08-12](/filings/0001104659-26-094907.md) (dei:EntityCommonStockSharesOutstanding).

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:28 ET. No prices; not investment advice.